Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 19Recurrence 5Sarcoma, Kaposi 2Neoplasms 2Acquired Immunodeficiency Syndrome 2Plasmacytoma 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 9fludarabine 5zanubrutinib 3Vincristine 3Rituximab 3Doxorubicin 3pirtobrutinib 2cemiplimab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Leukapheresis 2Immunotherapy, Adoptive 2Etoposide 2Dexamethasone 2Cell- and Tissue-Based Therapy 2tafasitamab 1sodium-iodide symporter 1selinexor 1ruxolitinib 1pomalidomide 1polatuzumab vedotin 1obinutuzumab 1ibrutinib 1glofitamab 1etoposide phosphate 1blinatumomab 1acalabrutinib 1X-Rays 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × pomalidomide × 30 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡